Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Ultragenyx Pharmaceutical (RARE) over the last 5 years, with Dec 2024 value amounting to $90.5 million.

  • Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) rose 4.48% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.8 million, marking a year-over-year increase of 4.48%. This contributed to the annual value of $90.5 million for FY2024, which is 23.11% up from last year.
  • According to the latest figures from FY2024, Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) is $90.5 million, which was up 23.11% from $73.5 million recorded in FY2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) peaked at $90.5 million during FY2024, and registered a low of $60.8 million during FY2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $78.0 million, with a median of $73.5 million in 2023.
  • Data for Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) shows a peak YoY grew of 23.11% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) stood at $60.8 million in 2020, then grew by 11.42% to $67.8 million in 2021, then grew by 3.13% to $69.9 million in 2022, then grew by 5.19% to $73.5 million in 2023, then increased by 23.11% to $90.5 million in 2024.